FTC Asks To Delay In-House PBM Insulin Case
By Jared Foretek · February 27, 2025, 10:29 PM EST
Arguing that pharmacy benefit managers accused of artificially inflating insulin prices have already "unreasonably delayed" discovery, the Federal Trade Commission is asking an in-house judge to push back an evidentiary trial...
To view the full article, register now.